Stemina Biomarker Discovery
Madison, US · Founded 2014 · Delaware corporation
Stemina Biomarker Discovery develops in vitro assays using human stem cell-derived cells to predict drug toxicity and support drug discovery and development. The company serves pharmaceutical and biotech firms seeking developmental and cardiac safety screening.
Founders & leadership
Stemina Biomarker Discovery was founded in 2014 by Elizabeth Donley and Gabriela Cezar.
Board
Reported raises · per SEC filings
Form D private placements$5.3M disclosed across 2 rounds · 2014–2016
▶$4.3MraisedJun 2016 · 29 investors · BiotechnologyRule 506(b)
- Andrew FerraraDirector
- R. Andrew MorganDirector
- Scott CarrDirector
- Kevin KrenitskyDirector
- Elizabeth L.R. DonleyExecutive Officer, Director
- Robert E. BurrierExecutive Officer
- Marc SchneebaumDirector
- Offering amount
- $7.1M
- Amount sold
- $4.3M
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1MraisedJun 2016 · 1 investors · BiotechnologyRule 506(b)
- Elizabeth L.R. DonleyExecutive Officer, Director
- Scott CarrDirector
- Marc SchneebaumDirector
- Andrew FerraraDirector
- R. Andrew MorganDirector
- Kevin KrenitskyDirector
- Robert BurrierExecutive Officer
- Offering amount
- $1.1M
- Amount sold
- $1M
- First sale
- May 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Stemina Biomarker Discovery for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 7 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $2.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $146.7K |
| National Science Foundation | Phase II | 2011 | $500K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2010 | $999.9K |
| National Science Foundation | Phase I | 2009 | $149.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $149.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Stemina Biomarker Discovery do?
- Stemina Biomarker Discovery develops in vitro assays using human stem cell-derived cells to predict drug toxicity and support drug discovery and development. The company serves pharmaceutical and biotech firms seeking developmental and cardiac safety screening.
- Who founded Stemina Biomarker Discovery?
- Stemina Biomarker Discovery was founded by Elizabeth Donley, Gabriela Cezar in 2014.
- How much funding has Stemina Biomarker Discovery raised?
- Stemina Biomarker Discovery has disclosed $5.3M raised across 2 rounds.
- Where is Stemina Biomarker Discovery headquartered?
- Stemina Biomarker Discovery is headquartered in Madison, US.